Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02204332
Other study ID # RLL-CAB-2011-01
Secondary ID
Status Terminated
Phase Phase 2
First received July 23, 2014
Last updated July 29, 2014
Start date March 2013

Study information

Verified date July 2014
Source Hospital Clinico Universitario de Santiago
Contact n/a
Is FDA regulated No
Health authority Spain: Spanish Agency of Medicines
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine efficacy and safety of cabazitaxel administration in patients with colorectal cancer resistant to standard treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 38
Est. completion date
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients who have given written informed consent.

- Men and women aged = 18 years.

- Patients with histologically confirmed metastatic advanced colorectal cancer without the possibility of potentially curative treatment.

- Patients with a life expectancy more than three months.

- Patients with advanced colorectal cancer in progression after receiving standard treatment.

- Patients with grade 0-2 functional status, according to Eastern Cooperative Oncology Group (ECOG).

- Patients with evaluable tumor by RECIST criteria.

- Patients recovered and with a degree less than or equal to 1, or baseline of all important pre-treatment-related AEs (excluding alopecia).

- Ability and willingness of the patient to consent to participation in the study.

- Ability to understand and comply with study procedures.

Exclusion Criteria:

- Patients with a performance status greater than 2, as Eastern Cooperative Oncology Group (ECOG).

- Inadequate marrow reserve, within 7 days prior to randomization:

- absolute neutrophil count <1.5 x 109 / L

- Hemoglobin <9.0 g / dL

- Platelet count <100 x 109 / L

- Inadequate liver function within 7 days prior to randomization:

- AST (SGOT) and ALT (SGPT)> 3.0 x ULN or 5> x ULN in case of abnormal liver function due to underlying liver metastases.

- Alkaline phosphatase> 3 × ULN (or 5 times the ULN if due to underlying liver metastases).

- Total bilirubin> 1.5 x ULN.

- Previous history of other malignancy, except for skin basal or squamous cell cancer with proper treatment, or in situ cervical cancer, or other cancers, in which the patient has been free of the disease in the last 5 years.

- Simultaneous treatment with concomitant anticancer therapy.

- History of brain metastases, uncontrolled compression of spinal cord, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease pathologies.

- Acquired Immunodeficiency Syndrome (AIDS-related diseases) or human immunodeficiency virus (HIV) or conditions requiring antiretroviral therapy virus.

- symptomatic grade = 2 peripheral sensory neuropathy, according to NCI-CTCAE v4.0.

- Any severe acute or chronic medical condition that may affect the patient's ability to participate in the study, or may lead to unacceptable security risks and non-compliance with protocol procedures or may interfere with the interpretation of the study results.

- Pregnant women or who are breastfeeding. Pregnancy assessment will be conducted by a test serum or urine during the 7 days prior to randomization.

- Patient (male or female) of reproductive age who still disagrees with the use of effective contraception during the treatment period and for at least 3 months after completion of the treatment period of the study. The definition of "effective method of birth control" is the opinion of the investigator.

- Participation in another clinical trial with an investigational drug and / or an investigational drug as adjunctive therapy within 30 days prior to randomization.

- Concomitant treatment with prohibited drugs as potent inhibitors or inducers of cytochrome P450 3A4.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Cabazitaxel

Other:
Best Supportive Care


Locations

Country Name City State
Spain Hospital German Trias i Pujol Badalona
Spain Hospital Arnau de Vilanova Lérida
Spain Hospital Ramón y Cajal Madrid
Spain Hospital Carlos Haya Málaga
Spain CHU de Orense Orense
Spain Hospital Clinico de Santiago Santiago de Compostela
Spain Hospital General de Valencia Valencia
Spain Hospital Miguel Servet Zaragoza

Sponsors (2)

Lead Sponsor Collaborator
Hospital Clinico Universitario de Santiago Fundación Ramón Domínguez

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Overall survival (OS) From date of randomization to death from any cause or until 24 months from enrolment No
Other Safety and toxicity in the experimental arm. Toxicity is graded according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE, v 4.0). From the date the informed consent is signed up to 30 days after the last dose Yes
Primary The efficacy of cabazitaxel measured by estimating the overall response rate (ORR), as the percentage of individuals who achieve a complete tumor response (CR) or partial tumor response (PR) in each arm and between arms. From date of randomization to disease progression or until 24 months from enrolment No
Secondary Progression-free survival (PFS) From randomisation to either documented disease progression or death from any cause or until 24 months from enrolment (whichever occurs earlier) No
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A